News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces topline outcomes from a phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD).
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announces that it has been awarded a grant for up to $17.8 million from the Bill & Melinda Gates Foundation. This will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid (DELTYBA® is the brand name where approved outside the U.S.) and Johnson & Johnson’s bedaquiline (SIRTURO® is the brand name), for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Otsuka Pharmaceutical Development & Commercialization, Inc., announces that it has entered a three-year collaboration with Holmusk Inc., a global data science and digital health company building the world’s largest real-world evidence (RWE) platform for behavioral health.
The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded grants to 10 organizations committed to the decriminalization of mental illness by ensuring the effective implementation of 988 as the nationwide mental health crisis hotline that goes live in July, 2022 and by increasing access to mental healthcare in communities across the United States.